Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centre for Translational Omics - |
RCV000049488 | SCV000778572 | likely pathogenic | Glycine encephalopathy | 2018-03-16 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000049488 | SCV000958225 | pathogenic | Glycine encephalopathy | 2024-01-09 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 830 of the GLDC protein (p.Thr830Met). This variant is present in population databases (rs386833560, gnomAD 0.03%). This missense change has been observed in individual(s) with non-ketotic hyperglycinemia (PMID: 27362913). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 56079). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GLDC protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. |
Juha Muilu Group; Institute for Molecular Medicine Finland |
RCV000049488 | SCV000081922 | probable-pathogenic | Glycine encephalopathy | no assertion criteria provided | not provided | Converted during submission to Likely pathogenic. | |
Natera, |
RCV000049488 | SCV001457114 | pathogenic | Glycine encephalopathy | 2020-09-16 | no assertion criteria provided | clinical testing |